Trevor Morin, Ph.D.

Trevor Morin, Ph.D. has a diverse work experience spanning multiple industries. Trevor is currently serving as the Vice President of Research and Development at GrapheneDx. Prior to this role, they worked at T2 Health Tech Consulting as a Technical Due Diligence and Market Analyst, where they performed technology due diligence for venture capitalist firms and scouted innovative technologies.

Morin also worked at IDEXX, first as an Associate Director and later as the Director of R&D, Discovery and Technology Futures. In these roles, they contributed to the advancement of the company's technology and collaborated with the executive team to define scientific and business objectives.

Before IDEXX, Morin served as the Chief Scientific Officer at Ontera, where they optimized the company's technology platform and facilitated its commercialization. Trevor was responsible for securing development deals, establishing industry partnerships, and creating patentable intellectual property.

Morin's earlier experience includes working as a Researcher in Biomolecular Engineering at the University of California, Santa Cruz, where they focused on developing an HIV vaccine. Trevor also worked at MassBiologics, where they led the discovery and development of therapeutic monoclonal antibodies.

Furthermore, Morin pursued their Ph.D. at the University of Massachusetts Medical School, conducting research on KCNQ1/KCNE Kᵦ Channel Complex. Trevor also worked as a Manager at the DNA Sequencing Facility and Researcher at the University of Massachusetts Boston.

Prior to their career in the sciences, Morin worked as a Thoroughbred rider and Trainer at various racing tracks along the East Coast.

Overall, Trevor Morin, Ph.D. has a strong background in research and development, technology due diligence, and collaboration with industry partners.

Trevor Morin, Ph.D., began their education at Mount Ida College from 1996 to 2000, where they pursued a Bachelor of Science degree in Animal Science with a concentration in Equine Science. Following this, from 2000 to 2002, they attended the University of Massachusetts, Boston, and earned a Bachelor of Science degree in Biology and Chemistry, specializing in Biochemistry. Lastly, they enrolled at UMass Chan Medical School from 2003 to 2008, where they obtained their Ph.D. degree in Biochemistry and Molecular Pharmacology.